DARE BIOSCIENCE INC (DARE) Stock Fundamental Analysis

NASDAQ:DARE • US23666P2002

1.65 USD
-0.02 (-1.2%)
Last: Feb 20, 2026, 08:26 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Overall DARE gets a fundamental rating of 1 out of 10. We evaluated DARE against 191 industry peers in the Pharmaceuticals industry. DARE has a bad profitability rating. Also its financial health evaluation is rather negative. DARE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • DARE had negative earnings in the past year.
  • DARE had a negative operating cash flow in the past year.
  • DARE had negative earnings in each of the past 5 years.
  • In the past 5 years DARE reported 4 times negative operating cash flow.
DARE Yearly Net Income VS EBIT VS OCF VS FCFDARE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -13.18%, DARE is in the better half of the industry, outperforming 64.40% of the companies in the same industry.
  • DARE has a Return On Equity of -141.84%. This is in the lower half of the industry: DARE underperforms 70.16% of its industry peers.
Industry RankSector Rank
ROA -13.18%
ROE -141.84%
ROIC N/A
ROA(3y)-76.89%
ROA(5y)-132.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DARE Yearly ROA, ROE, ROICDARE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K -6K -8K

1.3 Margins

  • DARE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DARE Yearly Profit, Operating, Gross MarginsDARE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • DARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, DARE has more shares outstanding
  • Compared to 5 years ago, DARE has less shares outstanding
  • DARE has a worse debt/assets ratio than last year.
DARE Yearly Shares OutstandingDARE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
DARE Yearly Total Debt VS Total AssetsDARE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -10.38, we must say that DARE is in the distress zone and has some risk of bankruptcy.
  • DARE has a worse Altman-Z score (-10.38) than 70.16% of its industry peers.
  • A Debt/Equity ratio of 1.88 is on the high side and indicates that DARE has dependencies on debt financing.
  • The Debt to Equity ratio of DARE (1.88) is worse than 78.01% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.88
Debt/FCF N/A
Altman-Z -10.38
ROIC/WACCN/A
WACC9.08%
DARE Yearly LT Debt VS Equity VS FCFDARE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 1.18 indicates that DARE should not have too much problems paying its short term obligations.
  • DARE's Current ratio of 1.18 is on the low side compared to the rest of the industry. DARE is outperformed by 81.15% of its industry peers.
  • DARE has a Quick Ratio of 1.18. This is a normal value and indicates that DARE is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.18, DARE is not doing good in the industry: 74.35% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.18
Quick Ratio 1.18
DARE Yearly Current Assets VS Current LiabilitesDARE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • DARE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -218.64%.
  • DARE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -99.65%.
EPS 1Y (TTM)-218.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.09%
Revenue 1Y (TTM)-99.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • DARE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 71.78% yearly.
  • The Revenue is expected to grow by 188.14% on average over the next years. This is a very strong growth
EPS Next Y-223.65%
EPS Next 2Y14.61%
EPS Next 3Y55.84%
EPS Next 5Y71.78%
Revenue Next Year-72.64%
Revenue Next 2Y390.72%
Revenue Next 3Y261.34%
Revenue Next 5Y188.14%

3.3 Evolution

DARE Yearly Revenue VS EstimatesDARE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
DARE Yearly EPS VS EstimatesDARE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DARE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DARE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DARE Price Earnings VS Forward Price EarningsDARE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DARE Per share dataDARE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

  • DARE's earnings are expected to grow with 55.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.61%
EPS Next 3Y55.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • DARE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DARE BIOSCIENCE INC

NASDAQ:DARE (2/20/2026, 8:26:33 PM)

1.65

-0.02 (-1.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13
Earnings (Next)03-30
Inst Owners7.07%
Inst Owner Change13.44%
Ins Owners0.71%
Ins Owner Change0%
Market Cap23.58M
Revenue(TTM)9.80K
Net Income(TTM)-4.05M
Analysts82
Price Target10.97 (564.85%)
Short Float %2.38%
Short Ratio1.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.49%
Min EPS beat(2)23.04%
Max EPS beat(2)23.94%
EPS beat(4)3
Avg EPS beat(4)10.74%
Min EPS beat(4)-19.49%
Max EPS beat(4)23.94%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-95.4%
Min Revenue beat(2)-110.91%
Max Revenue beat(2)-79.89%
Revenue beat(4)0
Avg Revenue beat(4)-96.8%
Min Revenue beat(4)-110.91%
Max Revenue beat(4)-79.89%
Revenue beat(8)0
Avg Revenue beat(8)-85.89%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.57%
EPS NY rev (1m)-6.8%
EPS NY rev (3m)-6.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-24.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-28.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2405.97
P/FCF N/A
P/OCF N/A
P/B 8.25
P/tB 8.25
EV/EBITDA N/A
EPS(TTM)-1.88
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0
BVpS0.2
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.18%
ROE -141.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-76.89%
ROA(5y)-132.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 1.88
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 67.01%
Cap/Sales 7565.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.18
Quick Ratio 1.18
Altman-Z -10.38
F-Score3
WACC9.08%
ROIC/WACCN/A
Cap/Depr(3y)1097.89%
Cap/Depr(5y)675.4%
Cap/Sales(3y)1956.65%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-218.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.09%
EPS Next Y-223.65%
EPS Next 2Y14.61%
EPS Next 3Y55.84%
EPS Next 5Y71.78%
Revenue 1Y (TTM)-99.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-72.64%
Revenue Next 2Y390.72%
Revenue Next 3Y261.34%
Revenue Next 5Y188.14%
EBIT growth 1Y24.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y83.31%
OCF growth 3YN/A
OCF growth 5YN/A

DARE BIOSCIENCE INC / DARE FAQ

Can you provide the ChartMill fundamental rating for DARE BIOSCIENCE INC?

ChartMill assigns a fundamental rating of 1 / 10 to DARE.


Can you provide the valuation status for DARE BIOSCIENCE INC?

ChartMill assigns a valuation rating of 1 / 10 to DARE BIOSCIENCE INC (DARE). This can be considered as Overvalued.


How profitable is DARE BIOSCIENCE INC (DARE) stock?

DARE BIOSCIENCE INC (DARE) has a profitability rating of 1 / 10.


How financially healthy is DARE BIOSCIENCE INC?

The financial health rating of DARE BIOSCIENCE INC (DARE) is 1 / 10.